Digitalni repozitorij raziskovalnih organizacij Slovenije

Izpis gradiva
A+ | A- | Pomoč | SLO | ENG

Naslov:Establishment of a virtual transborder tumor board for cancer patients in Central and Southeastern Europe : an initiative of the Central European Cooperative Oncology Group (CECOG)
Avtorji:ID Thallinger, Christiane (Avtor)
ID Berzinec, Peter (Avtor)
ID Bicakcic, Emina (Avtor)
ID Dan, Adelina (Avtor)
ID Fabian, Gabriella (Avtor)
ID Gales, Laurentia Nicoletta (Avtor)
ID Grašič-Kuhar, Cvetka, Onkološki inštitut (Avtor)
ID Janžič, Urška, Klinika Golnik (Avtor)
ID Mencinger, Marina, Onkološki inštitut (Avtor)
ID Zielinski, Christoph (Avtor)
Datoteke:.pdf PDF - Predstavitvena datoteka, prenos (1,14 MB)
MD5: F6D526A31B618E9D49B935C799F7E617
 
URL URL - Izvorni URL, za dostop obiščite https://link.springer.com/content/pdf/10.1007/s00508-022-02016-z.pdf
 
Jezik:Angleški jezik
Tipologija:1.01 - Izvirni znanstveni članek
Organizacija:Logo UKPBAG - Univerzitetna klinika za pljučne bolezni in alergijo Golnik
Povzetek:o establish a transborder virtual tumor board (VTB) fostering state-of-the-art management of cancer patients by exchanging knowledge and expertise among oncologists in Central and Southeastern Europe (CEE). Methods: We established and implemented a VTB based on the WebEx platform. This allowed for password-protected and secure upload of patient cases to be presented and discussed among colleagues from various oncology centers scattered throughout CEE in order to arrive at a recommendation for further diagnoses and/or treatment. Results: A total of 73 cases from 16 oncology centers located in 11 CEE countries were uploaded by 22 physicians; 71 were discussed over the course of 17 virtual meetings between June 2018 and May 2019 and 12 different kinds of malignant diseases were discussed with lung cancer (46.6%), melanoma (19.2%) and bladder cancer (13.6%) being the most commonly presented tumor entities. Of the discussed patients, 93.3% had stage IV disease at the time of presentation, 62.6% received chemotherapy or targeted treatment and 67.1% were treated with immune checkpoint inhibitors (ICPIs). The most common causes for presentation and discussion of patient cases were related to the use of ICPIs (80%). Conclusion: When the need for expertise exceeds locally available resources, web-based VTBs provide a feasible way to discuss patient cases and arrive at conclusions regarding diagnoses and/or treatment across large geographic distances. Moreover, VTBs provide an innovative way for proper, state-of-the-art management of patients with malignant diseases in times of social distancing and the resulting need for restricted interaction during the current SARS-CoV‑2 (severe acute respiratory syndrome coronavirus type 2) pandemic.
Ključne besede:CECOG, Osrednja in jugovzhodna Evropa, nadzorni imunski zaviralci, maligne bolezni
Status publikacije:V tisku
Verzija publikacije:Objavljena publikacija
Kraj izida:Avstrija
Založnik:Springer Nature
Leto izida:2022
Št. strani:str. [1-8]
Številčenje:Vol. , no.
PID:20.500.12556/DiRROS-14941 Novo okno
UDK:616-006
ISSN pri članku:0043-5325
DOI:10.1007/s00508-022-02016-z Novo okno
COBISS.SI-ID:102525955 Novo okno
Avtorske pravice:© The Author(s)
Opomba:Soavtorice iz Slovenije: Cvetka Grašič Kuhar, Marina Mencinger, Urška Janžič;
Datum objave v DiRROS:31.03.2022
Število ogledov:1084
Število prenosov:647
Metapodatki:XML DC-XML DC-RDF
:
Kopiraj citat
  
Objavi na:Bookmark and Share


Postavite miškin kazalec na naslov za izpis povzetka. Klik na naslov izpiše podrobnosti ali sproži prenos.

Gradivo je del revije

Naslov:Wiener Klinische Wochenschrift
Skrajšan naslov:Wien. Klin. Wochenschr.
Založnik:Springer
ISSN:0043-5325
COBISS.SI-ID:5473799 Novo okno

Licence

Licenca:CC BY 4.0, Creative Commons Priznanje avtorstva 4.0 Mednarodna
Povezava:http://creativecommons.org/licenses/by/4.0/deed.sl
Opis:To je standardna licenca Creative Commons, ki daje uporabnikom največ možnosti za nadaljnjo uporabo dela, pri čemer morajo navesti avtorja.
Začetek licenciranja:15.02.2022

Sekundarni jezik

Jezik:Ni določen
Ključne besede:CECOG, Central and Southeastern Europe, immune checkpoint inhibitors, malignant diseases


Nazaj